Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1905 single subcutaneous dose in adolescents with asthma (PK/PD, safety, preliminary efficacy)
CTR20250088Phase 2Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-1905 in asthma, sponsored by Hengrui Therapeutics. Started Jan 2025; status: completed.
02
Drugs
SHR-1905
03
Conditions
asthma
Beyond the preview
Go deeper on CTR20250088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250088.